Since Src kinase inhibitors decrease brain injury produced by intracerebral hemorrhage (ICH) and thrombin is activated following ICH, this study determined whether Src kinase inhibitors decrease thrombininduced brain injury. Thrombin injections into adult rat striatum produced focal infarction and motor deficits. The Src kinase inhibitor PP2 decreased thrombin-induced Src activation, infarction in striatum and motor deficits in vivo. Thrombin applied to cultured post-mitotic striatal neurons caused: injury to axons and dendrites; many TUNEL positive neuronal nuclei; and re-entry into the cell cycle as manifested by cyclin D1 expression, induction of several other cell cycle genes and cyclin-dependent kinase 4 activation. PP2 dose-dependently attenuated thrombin-induced injury to the cultured neurons; and attenuated thrombin-induced neuronal cell cycle re-entry. These results are consistent with the hypotheses that Src kinase inhibitors decrease injury produced by ICH by decreasing thrombin activation of Src kinases and, at least in part, by decreasing Src induced cell cycle re-entry. Published by Elsevier Inc.
Introduction
Intracerebral hemorrhages (ICH), which account for 10-15% of all strokes, have a very high morbidity and mortality (Ariesen et al., 2003) . ICH activates thrombin, which is a major contributor to ICH induced brain injury (Xi et al., 2003a; Xi et al., 2006) . Though thrombin is neuroprotective at low concentrations (Vaughan et al., 1995; Donovan and Cunningham, 1998; Striggow et al., 2000; Friedmann et al., 2001; Xi et al., 2003b) , it is detrimental at high concentrations (Donovan et al., 1997; Xi et al., 2003a; Xue et al., 2006; Fujimoto et al., 2007) . Direct infusion of 20 U of thrombin into rat brain causes a lesion with brain edema formation and neuronal death (Fujimoto et al., 2007) . Thrombin mediates the acute brain edema caused by ICH since thrombin inhibitors block the acute edema (Xi et al., 2003a; Xue et al., 2006) . The mechanisms by which thrombin injures the brain are still under study and are the subject of this report.
Thrombin-triggered receptor signaling is mediated in part via activation of protease-activated receptors (Biscardi et al., 2000) , which contribute to the subsequent brain injury (Wang and Reiser, 2003) . Inhibiting protease-activated receptors (PARs) decreases thrombin-induced brain injury (Xue et al., 2006) . However, PAR inhibitors may not be good treatment targets for ICH since these might affect the clotting and hemostatic functions of thrombin needed to halt progression of ICH (Thomas and Brugge, 1997).
PARs modulate several intracellular molecules including Src kinases. The Src family of nonreceptor tyrosine kinases is represented by at least eight different protein tyrosine kinases, including c-Src, c-Yes, Fyn, Lck, Lyn, Hck, Blk and c-Fgr (Oda et al., 1999; Biscardi et al., 2000) . Our genomic studies showed that the expression of Lyn, one of the Src family kinases, was up-regulated 21-fold following ICH (Tang et al., 2002; Lu et al., 2006) . This led us to test the role of Src kinase inhibitors in ICH. Src kinase inhibitors, which are less likely to affect coagulation (Thomas and Brugge, 1997), decreased glucose hypermetabolism and cell death around ICH and improved behavioral deficits following ICH (Ardizzone et al., 2007) . These results led to the current experiments that determined whether the improvement observed following ICH treated with Src kinase inhibitors was due, at least in part, to Src kinase inhibitors blocking thrombin and thrombin signaling.
Finally, both thrombin and Src kinases affect the cell cycle that may be important in ICH mediated cell death. Thrombin actions in the brain are associated with mitogen-activated protein kinase (MAPK) signaling (Fujimoto et al., 2007) . In cortical neuronal cultures, the mitogenic signaling by thrombin causes neurons to re-
